Press Releases:
February 12, 2008
Sapphire Therapeutics Promotes Suzan Allen to Vice President Clinical Operations
October 30, 2007
Sapphire Therapeutics Licenses Ghrelin Antagonist Program from Novo Nordisk for Development of Obesity Treatments
August 13, 2007
Sapphire Therapeutics Announces Promotions and New Appointment to Management Team
April 26, 2007
Sapphire Therapeutics, Inc. to Present Results from Anamorelin Phase 2 Cachexia/Anorexia Studies at ASCO and ENDO Annual Meetings in June Ono Plans Japanese Phase 1 Study
October 26, 2006
Sapphire Therapeutics, Inc. Licenses Novel Drug to Ono Pharmaceuticals in Japan, Korea and Taiwan for the Treatment of Cancer Anorexia/Cachexia
September 19, 2006
Sapphire Therapeutics, Inc. Licenses Ghrelin Mimetic from Novo Nordisk Ipamorelin to enter Phase II for postoperative ileus
August 25, 2006
Sapphire Therapeutics, Inc. Expands Drug Development Team
January 17, 2006
Sapphire Therapeutics, Inc. Appoints New Director and Scientific Advisory Board to Support
January 6, 2006
Sapphire Therapeutics, Inc. Builds Drug Development Team through New Hires and Promotion
December 15, 2005
Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
October 5, 2005
Rejuvenon Corporation. changes name to Sapphire Therapeutics
July 20, 2005
Rejuvenon’s RC-8800 for Prostate Cancer Enters Human Testing
January 10, 2005
Rejuvenon’s RC-1291 Ghrelin Mimetic Receives Fast TrackDesignation from FDA for Cancer Anorexia/Cachexia
For other media inquiries, please send an email to generalinfo@sapphirethera.com.
|
